ClinicalTrials.gg
CompletedNCT02637076Updated Mar 23, 2021Results posted

Xyrem and Brain Dopamine in Narcolepsy

A Phase 4 interventional study of Xyrem in Narcolepsy With Cataplexy and Healthy Controls, sponsored by Centre for Addiction and Mental Health. Completed at 1 site in Canada. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.

Sponsored by Centre for Addiction and Mental Health · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies in Narcolepsy with a site in Canada — 4 open to participants now, 4 under way, 2 of them phase 3. Narcolepsy · Canada.

Enrollment
22nd of 23
17 · median 150
Started
2016
with 1 other
Phase 4
2 of 24
none open now
Registered
9th of 24
by date
Lead sponsor
1 of 24
Centre for Addiction and Mental Health

Among the 24 studies in Narcolepsy with a site in Canada, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2016, is one of 2 in phase 4, and was the 9th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 24 studies in Narcolepsy with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Narcolepsy with a site in Canada, or all of them as a file.
02

Study summary

The overall aim of this investigation is to establish whether an action of Xyrem® on the brain dopamine system in patients with narcolepsy, and in a comparison control group, might explain part of the anti-narcoleptic effect of the drug.

Trial Objective is to establish, using positron emission tomography (PET), in Xyrem®-naïve narcolepsy with cataplexy patients, and in matched controls, whether a single dose of Xyrem® causes changes in striatal binding of 11C-raclopride and 11C-DTBZ that would suggest altered activity of brain dopamine neurones.

03

Conditions studied

  • Narcolepsy With Cataplexy
  • Healthy Controls

Browse trials for

Keywords

  • Xyrem
  • narcolepsy with cataplexy
  • positron emission tomography
  • dopamine
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • current diagnosis of narcolepsy with cataplexy OR healthy control

Exclusion criteria

Exclusion Criteria:

  • use of any sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine at start of baseline period
  • significant unstable or uncontrolled medical/psychiatric disease
  • significant history of head trauma/surgery or seizure disorder
  • radiation exposure exceeding 20mSv in last 12 months
  • pregnancy
  • substance abuse/dependence (including alcohol)
  • have sleep apnea, or are shift workers
  • on a sodium-restricted diet
  • has ever taken Xyrem / sodium oxybate / GHB at any time
  • claustrophobia
  • metal implants / objects in the body that may interfere with MRI
  • succinic semialdehyde dehydrogenase deficiency
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    narcolepsy with cataplexy

    patients given single dose of Xyrem

    Drug: Xyrem

  • Experimental
    healthy controls

    healthy controls given a single dose of Xyrem

    Drug: Xyrem

Interventions

  • DrugXyrem

    single 3.0 gram dose

    Also known as: Sodium Oxybate, gamma-hydroxybutyrate

06

What researchers measure

Primary outcomes

  1. [C-11]Raclopride BPND at 1 Hour Post Xyrem

    BPND (Binding Potential) of \[C-11\]raclopride measures 1 hour after taking a single 3g dose of Xyrem.

    Time frame: 1 hour post Xyrem

  2. % Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem

    \[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.

    Time frame: 1 hour post Xyrem

  3. [C-11]Raclopride BPND at 7 Hours Post Xyrem

    BPND (Binding Potential) of \[C-11\]raclopride measures 7 hours after taking a single 3g dose of Xyrem.

    Time frame: 7 hours post Xyrem

  4. % Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem

    \[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.

    Time frame: 7 hours post Xyrem

Secondary outcomes

  1. [C-11]DTBZ BPND at 5 Hours Post Xyrem

    Measurement of \[C-11\]DTBZ 5 hours after taking a single dose of 3g Xyrem

    Time frame: 5 hours post single Xyrem dose

  2. % Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem

    \[C-11\] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy. % change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.

    Time frame: 5 hours post single Xyrem dose

  3. Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)

    The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.

    Time frame: multiple time points from 0 to 7 hours post-Xyrem

  4. Blood Gamma-hydroxybutyrate (GHB) Cmax

    The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.

    Time frame: multiple time points from 0 to 7 hours post-Xyrem

  5. Duration of Drowsiness

    Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.

    Time frame: observed after receiving single dose of Xyrem, up to 9 hours

07

Results

Posted Mar 23, 2021

Participant flow

Participant flow — Overall Study
MilestoneNarcolepsy With CataplexyHealthy Controls
Started215
Completed110
Not completed15
Withdrew: Due to technical difficulties, the 1 hour post pet scan was not completed at the one hour time point11
Withdrew: Withdrawal by subject04

Outcome measures

Primary[C-11]Raclopride BPND at 1 Hour Post Xyrem

BPND (Binding Potential) of \[C-11\]raclopride measures 1 hour after taking a single 3g dose of Xyrem.

Time frame:
1 hour post Xyrem
Reported as:
Mean · BPND (Binding Potential)
[C-11]Raclopride BPND at 1 Hour Post Xyrem
BPND (Binding Potential)Narcolepsy With CataplexyHealthy Controls
Limbic Striatum2.943.01 ± 0.28
Associate Striatum3.803.70 ± 0.33
Sensorimotor Striatum3.874.11 ± 0.49
Statistical analysis
  • Healthy Controls · repeated measures ANOVA · p = 0.31F(2,36)=1.26
Primary% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem

\[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.

Time frame:
1 hour post Xyrem
Reported as:
Mean · percentage change from baseline
% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem
percentage change from baselineNarcolepsy With CataplexyHealthy Controls
Limbic Stiatum13.276.49 ± 8.60
Associative Striatum23.882.11 ± 8.59
Sensorimotor Striatum24.431.93 ± 8.85
Primary[C-11]Raclopride BPND at 7 Hours Post Xyrem

BPND (Binding Potential) of \[C-11\]raclopride measures 7 hours after taking a single 3g dose of Xyrem.

Time frame:
7 hours post Xyrem
Reported as:
Mean · BPND (Binding Potential)
[C-11]Raclopride BPND at 7 Hours Post Xyrem
BPND (Binding Potential)Narcolepsy With CataplexyHealthy Controls
Limbic Striatum2.332.76 ± 0.18
Associate Striatum2.833.62 ± 0.29
Sensorimotor Striatum2.754.06 ± 0.40
Primary% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem

\[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.

Time frame:
7 hours post Xyrem
Reported as:
Mean · percentage change from baseline
% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem
percentage change from baselineNarcolepsy With CataplexyHealthy Controls
Limbic Striatum-10.13-2.07 ± 8.24
Associative Striatum-7.500.17 ± 7.42
Sensorimotor Striatum-11.560.72 ± 7.64
Secondary[C-11]DTBZ BPND at 5 Hours Post Xyrem

Measurement of \[C-11\]DTBZ 5 hours after taking a single dose of 3g Xyrem

Time frame:
5 hours post single Xyrem dose
Reported as:
Mean · BPND (binding potential)
[C-11]DTBZ BPND at 5 Hours Post Xyrem
BPND (binding potential)Narcolepsy With CataplexyHealthy Controls
Limbic Striatum1.711.82 ± 0.24
Associative Striatum2.562.65 ± 0.40
Sensorimotor Striatum2.653.12 ± 0.53
Secondary% Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem

\[C-11\] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy. % change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.

Time frame:
5 hours post single Xyrem dose
Reported as:
Mean · percentage change from baseline
% Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem
percentage change from baselineNarcolepsy With CataplexyHealthy Controls
Limbic Striatum2.00-1.98 ± 9.20
Associative Striatum6.102.04 ± 11.84
Sensorimotor Striatum6.512.47 ± 12.09
Statistical analysis
  • Healthy Controls · repeated measures ANOVA · p = 0.748
SecondaryBlood Gamma-hydroxybutyrate (GHB) Concentration (AUC)

The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.

Time frame:
multiple time points from 0 to 7 hours post-Xyrem
Reported as:
Mean · AUC (ug/ml*hr)
Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)
AUC (ug/ml*hr)Narcolepsy With CataplexyHealthy Controls
Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)187.03178.49 ± 52.12
SecondaryBlood Gamma-hydroxybutyrate (GHB) Cmax

The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.

Time frame:
multiple time points from 0 to 7 hours post-Xyrem
Reported as:
Mean · mg/ml
Blood Gamma-hydroxybutyrate (GHB) Cmax
mg/mlNarcolepsy With CataplexyHealthy Controls
Blood Gamma-hydroxybutyrate (GHB) Cmax107107.37 ± 32.95
SecondaryDuration of Drowsiness

Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.

Time frame:
observed after receiving single dose of Xyrem, up to 9 hours
Reported as:
Median · minutes
Duration of Drowsiness
minutesNarcolepsy With CataplexyHealthy Controls
Duration of Drowsiness220.2092.4 (10.02 to 285.00)

Adverse events

Collected over Adverse events will be assessed at each study visit following administration of the first PET radiotracer until the follow-up phone after Xyrem administration (2 visits plus 1 follow-up phone call), an average of 10 days per participant.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Narcolepsy With Cataplexy0/2 (0%)0/2 (0%)0/2 (0%)
Healthy Controls0/15 (0%)0/15 (0%)4/15 (26.7%)
Most frequent other events
Most frequent other events
EventNarcolepsy With CataplexyHealthy Controls
NauseaGeneral disorders0/23/15
EuphoriaGeneral disorders0/21/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Narcolepsy With CataplexyHealthy ControlsTotal
Mean5229.6 ± 831.6 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)Narcolepsy With CataplexyHealthy ControlsTotal
Female145
Male066
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Narcolepsy With CataplexyHealthy ControlsTotal
Hispanic or Latino000
Not Hispanic or Latino11011
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Narcolepsy With CataplexyHealthy ControlsTotal
American Indian or Alaska Native000
Asian066
Native Hawaiian or Other Pacific Islander000
Black or African American000
White134
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Narcolepsy With CataplexyHealthy ControlsTotal
Canada11011
[C-11]raclopride BPND at Baseline
[C-11]raclopride BPND at Baseline(BPND (Binding Potential))Narcolepsy With CataplexyHealthy ControlsTotal
Limbic Striatum2.592.83 ± 0.192.80 ± 0.19
Associative Striatum3.063.63 ± 0.323.58 ± 0.35
Sensorimotor Striatum3.114.04 ± 0.433.96 ± 0.49
[C-11]DTBZ BPND at Baseline
[C-11]DTBZ BPND at Baseline(BPND (Binding Potential))Narcolepsy With CataplexyHealthy ControlsTotal
Limbic Striatum1.681.85 ± 0.191.84 ± 0.18
Associative Striatum2.412.60 ± 0.262.58 ± 0.25
Sensorimotor Striatum2.493.05 ± 0.383.00 ± 0.40
08

Study locations

1 site
  • Centre for Addiction and Mental Health (CAMH)
    Toronto, Ontario M5T 1R8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jan 2020 and a completion of Jan 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2015
First posted
Dec 22, 2015
Start
Jan 2016
Primary completionActual
Jan 23, 2020
CompletionActual
Jan 23, 2020
Results first posted
Mar 23, 2021
Last update
Mar 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02637076
Responsible party
Stephen Kish (Senior Scientist, Head Human Brain Lab, Centre for Addiction and Mental Health) — Principal investigator
First posted
Dec 22, 2015
Start date
Jan 2016
Primary completion
Jan 23, 2020
Completion
Jan 23, 2020
Results posted
Mar 23, 2021
Last update
Mar 23, 2021

Study contacts

Stephen J Kish, Ph.D.
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Oxybate

Start the discussion